Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HIV-1 capsid protein (CA) hexamer interface FG pocket is a highly conserved hydrophobic site located at the junction of the N-terminal domain of one CA subunit and the C-terminal domain of an adjacent subunit within the hexameric lattice (PubMed: 32612211). This pocket is a critical functional hotspot that mediates the interaction between the viral capsid and essential host cell factors, including the nuclear pore protein NUP153 and the cleavage and polyadenylation specificity factor 6 (CPSF6) (PubMed: 24336210). These interactions are vital for the nuclear import of the viral pre-integration complex and the subsequent integration of viral DNA into the host genome. Therapeutic agents such as Lenacapavir (Sunlenca) target this pocket with picomolar affinity, effectively locking the capsid and disrupting multiple stages of the viral lifecycle, including assembly, uncoating, and nuclear transport (Nature, 2020, 583:114-118). Because the FG pocket is essential for viral fitness and is highly conserved across different HIV-1 strains, it represents a high-value target for long-acting antiretroviral therapies (NEJM, 2022, 386:1793-1803). The development of inhibitors for this site has provided a new treatment modality for patients with multi-drug resistant HIV-1 infection.
Capsid inhibition via competitive binding at the FG pocket, which prevents interaction with host factors such as NUP153 and CPSF6, thereby disrupting capsid stability, uncoating, and nuclear transport (Nature, 2020, 583:114-118; PubMed: 32612211).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HIV-1 capsid protein (CA) hexamer interface FG pocket (HIV-1 CA FG pocket).